Category: Uncategorized

Expands Breadth of Nimbus Drug Discovery Network

CAMBRIDGE, Mass. – November 8, 2012 – Nimbus Discovery LLC, today announced that it has executed a Privileged Partnership Agreement with Proteros Biostructures GmbH (“Proteros”), Martinsried, Germany. This partnership will accelerate drug discovery efforts against a growing pipeline of medically important targets.

Nimbus joins a select number of prestigious pharmaceutical and biotechnology companies that have entered into Privileged Partnership Agreements with Proteros. Privileged Partners are able to preferentially access Proteros’ new Gallery Structures, technologies and extensive in-house expertise to accelerate structure-based drug discovery efforts.

Jonathan Montagu, Vice President, Business Development and Operations at Nimbus commented, “Our cutting-edge computational platform relies heavily upon high quality x-ray structure data. Hence, our current collaboration with Proteros has been instrumental in our success with previously inaccessible targets. This expanded partnership is a logical progression of how we are integrating leading edge technologies to create a new model for drug discovery.”

Cony D’Cruz, Chief Business Officer and President, Proteros, US Inc. added, “We are excited to expand our collaboration with Nimbus. The relationship has been very productive and we look forward to continuing to support Nimbus’ innovative and proven discovery platform.”

About Nimbus

Nimbus Discovery, a biotechnology company, harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. We focus on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches. Our robust pre-clinical pipeline includes novel agents for the treatment of cancer, metabolic disease and inflammation. Nimbus is organized as a constellation of small, nimble teams of experienced drug-hunters deployed across program-focused subsidiary companies. Each team is freed from conventional barriers to scientific success, chartered to create solutions, and geared for program asset deals with leading pharmaceutical companies. Founded in 2009, Nimbus partnered with Schrödinger to invent and apply a physics-based approach that establishes a new standard for rational drug design. Nimbus is backed by world-class life science investors; including Atlas Venture, SR One, Lilly Ventures and Gates Ventures. For more information please visit www.nimbustx.com.

About Proteros biostructures GmbH

Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables ‘knowledge driven lead engineering’ to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America. For more information please visit www.proteros.com.

DOWNLOAD PRESS RELEASE

CAMBRIDGE, Mass. – November 1, 2012 – Nimbus Discovery LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible disease targets, today announced that Daniel S. Lynch has been appointed to the company’s Board of Directors as Executive Chairman. Dan will succeed Bruce Booth, D. Phil., Partner at Atlas Venture and Co-Founder of Nimbus, who will remain on the Board.

“One of Dan’s many strengths is his ability to drive young companies to achieve their goals. In particular, his proven track record in creating value through partnerships will be important as we secure a series of program-focused transactions”, said Bruce Booth. “His expertise in strategy and executive management will provide a valuable resource to the Nimbus team and Board,” Booth added.

Previously, Dan was Executive Chairman at Avila (acquired by Celgene in 2012) and Stromedix (acquired by Biogen Idec in 2012). Dan has more than 25 years experience serving in management positions in the biotechnology and pharmaceutical industries. Dan was CEO and CFO at ImClone Systems, which he led through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX^® (cetuximab), a novel cancer treatment. Earlier, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure.

“Nimbus Discovery is successfully developing drugs for sought-after targets where traditional chemistry approaches have failed,” said Dan Lynch. “Nimbus has established a radically new approach to drug discovery that has the potential to transform the entire industry pipeline with innovative medicines.”

About Nimbus

Nimbus Discovery, a biotechnology company, harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. We focus on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches. Our robust pre-clinical pipeline includes novel agents for the treatment of cancer, metabolic disease and inflammation. Nimbus is organized as a constellation of small, nimble teams of experienced drug-hunters deployed across program-focused subsidiary companies. Each team is freed from conventional barriers to scientific success, chartered to create solutions, and geared for program asset deals with leading pharmaceutical companies. Founded in 2009, Nimbus partnered with Schrödinger to invent and apply a physics-based approach that establishes a new standard for rational drug design. Nimbus is backed by world-class life science investors, including Atlas Venture, SR One, Lilly Ventures and Gates Ventures. For more information please visit www.nimbustx.com.

DOWNLOAD PRESS RELEASE

By Patricia Resende (Mass High Tech)

April 20, 2012

Rosana Kapeller has always had the entrepreneurial bug and a love for science. While most of Kapeller’s family members believed she would join the high-powered family’s media business in her native Brazil, Kapeller had a different plan. With her MD in hand, she left Brazil to get her Ph.D. and join her husband-to-be Towia Libermann in Boston. She forged ahead in her role as scientist at Millennium Pharmaceuticals to director of its molecular and cellular biology department before co-founding Ailerion Therapeutics where she helped raise $60M million in capital. With support from her family in the Bay State and Brazil, the mother of three and chief scientific officer at Nimbus Discovery continues to balance her love for family and Brazilian culture with business and science.

Education: Kapeller started her post-secondary education at Faculdade de Ciencias Medicas de Universidade do Estado do Rio de Janeiro and graduated with a M.D. She left Brazil in 1987 to attend Tufts University Medical School, where she earned a Ph.D. in molecular and cellular physiology.

On her path to science: “I grew up in a family of publishers and journalists and there were few people in the family that stepped out to be a doctor. My interest was in bringing basic science and novel therapeutics to patients and I knew I couldn’t do that in Brazil.”

Mentor: “I had a ton of support from my family. My great uncle was the driving force of our business in Brazil. He was bigger than life and had a very big impact on my life. My dad is my biggest fan and supporter. We talk every day. He Skypes and FaceTime’s me.” Kapeller visits with her biggest fan on her during her annual trips to Brazil with her family each year.

Advice for women in technology: “One of the biggest challenges for women in science is they are never heard. When a women has an idea everyone nods to be polite. It sounds like a joke, but it is very real. They have ideas and solutions and get frustrated when others don’t see the value of it. I tell women to take ownership and teach them how to toot their own horn without being perceived as a witch.”

On finding balance: Something has to give in order to find work/life balance. “Women have what I like to call superwoman syndrome. They want to do everything perfect. They want to be head of the company, head of the PTO and have a neat and clean home, but they are not willing to accept help. The only reason I could do it was I always had a full-time nanny.”

Proudest accomplishment(s): Without a doubt, Kapeller said her biggest accomplishments in life are her children. “My son Allon, 20, daughter Dana, 18, and son Noah, 11.”

Biggest challenge: “My biggest challenge is the culture. It’s about Brazilian culture being an inclusive, friendly culture. Brazilians have a sense of authority. I’d be outspoken and blunt and nobody could really appreciate that. In meetings, I’d challenge the head of the company. That got me in trouble many times, but I’ve learned my lesson. Here you can’t do that you have to be polite and politically correct.”

Favorite device/gadget: “My iPad. I was at a meeting and I did everything with my iPad. It was like Star Trek.”

Bruce Booth, board member at Nimbus Discovery and partner at Atlas Ventures

“Rosana has already proven in her career that she is a results-driven leader. She genuinely cares about making a difference in this world and it shows in both her work and in the way she treats and respects those she works with.”

View a slideshow of the 2012 Women to Watch honorees.

 

DOWNLOAD PRESS RELEASE

Utility supercomputing leader facilitates massive cluster for computational drug discovery

NEW YORK, NY – (Marketwire) April 19, 2012 – Cycle Computing provisioned a 50,000-core utility supercomputer in the Amazon Web Services (AWS) cloud for Schrödinger and Nimbus Discovery to accelerate lead identification via virtual screening. This milestone – the largest of its kind – is Cycle Computing’s fifth massive cluster in less than two years on the heels of a 30,000 cluster in October 2011, illustrating Cycle’s continued leadership in delivering full-featured and scalable cluster deployments. Cycle Computing revealed the cluster creation during today’s opening keynote at the AWS Summit in New York City.

Schrödinger’s widely used computational docking application, Glide, performs high-throughput virtual screening of compound libraries for identification of drug discovery leads. Computing resource and time constraints traditionally limit the extent with which ligand conformations can be explored, potentially leading to false negative while the same constraints may require a less accurate level of scoring, which can lead to false positives. Tapping into Cycle’s utility supercomputing, Schrödinger ran a virtual screen in collaboration with Nimbus Discovery of 21 million compounds against a protein target. The run required 12.5 processor years and completed in less than three hours.

“Typically, we have to weigh tradeoffs between time and accuracy in a project,” said Ramy Farid, President, Schrödinger. “With Cycle’s utility supercomputing, we didn’t have to compromise the accuracy in favor of faster throughput, and we were able to run the virtual screen using the appropriate levels of scoring and sampling.”

The global 50,000-core cluster was run with CycleCloud, Cycle’s flagship HPC in the cloud service that runs on AWS. Replicating data across seven AWS regions while automating provisioned resources, CycleCloud run time per job averaged 11 minutes and the total work completed topped 100,000 hours. Schrödinger’s researchers completed over 4,480 days of work, nearing 12.5 years of computations in a few hours, with cost under $4,900 per hour at peak requiring no upfront capital.

“By leveraging AWS, Cycle Computing is able to perform highly sophisticated computations in minutes at a fraction of what it would cost for businesses to purchase the high performance computing infrastructure themselves,” said Terry Wise, Director of Business Development, Amazon Web Services. “Cycle Computing brings an incredible amount of innovation to our partner ecosystem and we’re excited to continue working with them to enable businesses to take advantage of AWS’s highly scalable, elastic and low cost technology infrastructure.”

Cluster and performance analytics software CycleServer tracked utilization, diagnosed performance and managed scientific workflow. Replicating the success of employing next generation developments, Cycle engineers continued open source strategies, including Condor, Linux, and Opscode’s Chef cloud infrastructure automation system. Cycle’s Chef monitoring and analytics plug-in, called Grill, provided visualization into scaling the infrastructure environment and eliminated the need for additional Chef servers with alert technology supporting data around installations, driving down preparation and operational overhead.

Leveraging CycleCloud software and Cycle’s HPC proficiency delivered these stats:

• Infrastructure: 6,742 Amazon EC2 instances /58.79 TB RAM
• Global-scale: Multi-datacenter clusters with simple user interfaces
• Cluster Size: 51,132 cores, 58.78TB RAM
• Security: Engineered with HTTPS, SSH & 256-bit AES encryption
• AWS Regions:7 (us-east, us-west1, us-west2, eu-west, sa-east, ap-northeast, ap-southeast)

The end-user experience for using CycleCloud is:

• User Effort: One-click global cluster at massive scale
• Start-up Time: Thousands of cores in minutes, full cluster in 2 hours
• Up-front Capital Investment: $0
• Total Infrastructure Cost: $4,828.85/hour

“Researchers can now meet their aspirations and bottom line through secure, mega-elastic and fully-supported utility supercomputers,” said Jason Stowe, founder and CEO, Cycle Computing. “By harvesting the raw infrastructure from AWS, we empower Schrödinger’s scientific accuracy while allowing them to push the boundaries of computation research. Creating robust, reliable and importantly repeatable supercomputers means any industry from life sciences, risk management, quantitative finance to product design can reap the benefits as we tip the scales towards the next generation of massive clusters.”

To learn more about the development of the 50,000 core-cluster and Cycle’s projects leading up to this accomplishment, please visit the Cycle Computing blog: Compute Cycles (http://blog.cyclecomputing.com/).

About Schrödinger

Schrödinger is a scientific leader in developing state-of-the-art simulation software for use in pharmaceutical and biotechnology research. The Company’s products range from a complete suite of drug design software employing both ligand- and structure-based methods to general molecular modeling programs. Additionally, the Seurat platform provides enterprise-wide data management, sharing, and visualization. Most recently, Schrödinger debuted BioLuminate for modeling biologics. The predictive power of Schrödinger’s software allows scientists to accelerate their research and development, reduce costs, and make novel discoveries. Schrödinger operates from locations in New York, Oregon, California, Massachusetts, Maryland, Germany, the UK, and Japan. For more information, visit www.schrodinger.com.

About Nimbus

Nimbus Discovery is applying advances in computer-based drug discovery to develop new medicines against important drug targets and thereby unlock fundamental biological pathways. Nimbus has established a first-of-its-kind partnership with Schrödinger, the leader in computational drug discovery, to gain privileged access to cutting-edge technology and exclusive rights to key targets. Nimbus has already delivered selective, potent, and differentiated compounds within the first year for two disease targets that are pivotal in the progression of an aggressive form of Non-Hodgkin’s lymphoma and obesity, respectively. Nimbus has built a virtually integrated, globally distributed R&D organization that leverages an experienced internal drug discovery team across an external network of R&D partners. The resulting organization is scalable, capital efficient and has attracted world-class talent. Nimbus seeks to partner its programs with larger pharmaceutical companies early in the development process allowing Nimbus to focus on its competitive advantage in novel drug discovery. Nimbus programs are held in target-specific subsidiaries under an LLC umbrella. Nimbus Discovery was founded in 2009 by Atlas Venture and Schrödinger, Inc. In 2010, Nimbus received three Qualifying Therapeutic Discovery Project Tax Credit (QTDP) grants for its programs. For more information please visit www.nimbustx.com.

About Cycle Computing

Cycle Computing is the leader in Utility Supercomputing software. As a bootstrapped, profitable software company, Cycle delivers proven, secure and flexible high performance computing (HPC) and data solutions since 2005. Cycle helps clients maximize existing infrastructure and speed computations on servers, VMs, and on-demand in the cloud. Our products help clients maximize internal infrastructure and increase power as research demands, like the 10000-core cluster for Genentech and the 30000+ core cluster for a Top 5 Pharma that were covered in Wired, TheRegister, BusinessWeek, Bio-IT World, and Forbes. Starting with three initial Fortune 100 clients, Cycle has grown to deploy proven implementations at Fortune 500s, SMBs and government and academic institutions including JP Morgan Chase, Purdue University, Pfizer and Lockheed Martin.

About Amazon Web Services

Launched in 2006, Amazon Web Services (AWS) began exposing key infrastructure services to businesses in the form of web services – now widely known as cloud computing. The ultimate benefit of cloud computing, and AWS, is the ability to leverage a new business model and turn capital infrastructure expenses into variable costs. Businesses no longer need to plan and procure servers and other IT resources weeks or months in advance. Using AWS, businesses can take advantage of Amazon’s expertise and economies of scale to access resources when their business needs them, delivering results faster and at a lower cost. Today, Amazon Web Services provides a highly reliable, scalable, low-cost infrastructure platform in the cloud that powers hundreds of thousands of enterprise, government and startup customers businesses in 190 countries around the world. AWS offers over 28 different services, including Amazon Elastic Compute Cloud (Amazon EC2), Amazon Simple Storage Service (Amazon S3) and Amazon Relational Database Service (Amazon RDS). AWS services are available to customers from data center locations in the U.S., Brazil, Europe, Japan and Singapore.

DOWNLOAD PRESS RELEASE

SR One and Lilly Ventures join financing as new investors

In vivo proof of concept achieved for lead IRAK4 program in 9 months

CAMBRIDGE, Mass. – June 28, 2011 – Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24MM Series A financing. The investment was co-led by Atlas Venture, SR One, and Lilly Ventures. Existing investor, Bill Gates, also participated.

“We are delighted to have the support of SR One and Lilly Ventures,” said Bruce Booth, Chairman and Co-founder of Nimbus. “Their investment recognizes the extraordinary progress that Nimbus has made with its platform including the discovery of highly selective IRAK4 inhibitors with potent in vivo activity.”

Proceeds from the financing will be used to accelerate existing programs targeting IRAK4 and ACC, in inflammation, cancer and metabolic disease, and to expand the Nimbus pipeline to include a series of new targets addressing important medical conditions. IRAK4 plays a pivotal role in inflammatory disease allowing the Nimbus drug candidates to be pursued in a broad range of therapeutic applications. IRAK4 is a genetically validated target since humans with inactivating IRAK4 mutations are resistant to autoimmune disease but are otherwise healthy in adulthood.

In connection with the financing, Kent Gossett, M.D., Ph.D., Partner at SR One, and Steve Hall, Ph.D., Venture Partner at Lilly Ventures, have joined the Nimbus Board of Directors.

“We are excited by the advances that Nimbus has made in unlocking previously intractable targets. We believe that the Nimbus approach can deliver medicines that will transform the treatment of serious disease,” Kent said.

“Nimbus Discovery has created a highly innovative drug discovery model that combines a unique collaboration with Schrödinger with single-minded focus on developing valuable drug candidates,” Steve added.

Steve and Kent join the existing Board of Directors that includes Bruce Booth, Ph.D., Partner at Atlas Venture (Director); Vicki Sato, Ph.D., former President of Vertex Pharmaceuticals (Director); and Ramy Farid, Ph.D., co-founder of Nimbus Discovery and President of Schrödinger (Director).

About Nimbus

Nimbus Discovery is applying advances in computer-based drug discovery to develop new medicines against important drug targets and thereby unlock fundamental biological pathways. Nimbus has established a first-of-its-kind partnership with Schrödinger, the leader in computational drug discovery, to gain privileged access to cutting-edge technology and exclusive rights to key targets. Nimbus has already delivered selective, potent, and differentiated compounds within the first year for two disease targets that are pivotal in the progression of an aggressive form of Non-Hodgkin’s lymphoma and obesity, respectively. Nimbus has built a virtually integrated, globally distributed R&D organization that leverages an experienced internal drug discovery team across an external network of R&D partners. The resulting organization is scalable, capital efficient and has attracted world-class talent. Nimbus seeks to partner its programs with larger pharmaceutical companies early in the development process allowing Nimbus to focus on its competitive advantage in novel drug discovery. Nimbus programs are held in target-specific subsidiaries under an LLC umbrella. Nimbus Discovery was founded in 2009 by Atlas Venture and Schrödinger, Inc. In 2010, Nimbus received three Qualifying Therapeutic Discovery Project Tax Credit (QTDP) grants for its programs. For more information please visit www.nimbustx.com.

About Atlas Venture

Atlas Venture is a leading early stage international venture capital firm that invests in technology and life sciences businesses. Since inception in 1980, its partners have helped build more than 350 companies in more than 16 different countries. Atlas Venture is currently investing from its eighth fund which closed in late 2008. For more information, visit www.atlasventure.com.

About SR One

SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science that will significantly impact medical care. Since 1985, SR One has invested approximately $650 million in more than 140 companies. For more information, visit www.srone.com.

Above Lilly Ventures

Lilly Ventures, one of the venture capital funds associated with Eli Lilly and Company, manages $200 million in committed capital, investing in start-up biopharmaceutical and medical technology companies in early through expansion-stage investments. The primary goal of Lilly Ventures is to facilitate the success of companies with innovative technologies by providing both financial and intellectual resources to accelerate the management teams’ path to success. For further information, visit www.lillyventures.com.

About Schrödinger

Schrödinger is a scientific leader in developing state-of-the-art chemical simulation software for use in pharmaceutical and biotechnology research. The Company provides products ranging from general molecular modeling programs to a full-featured suite of drug design software using both ligand- and structure-based methods. The predictive power of Schrödinger’s software allows scientists to accelerate their research and development activities, reduce research costs, and make novel discoveries that might not be possible otherwise. Most recently, Schrödinger acquired the Seurat™ platform to add enterprise-wide data sharing and visualization to its complete offerings. Schrödinger operates from locations in New York, Oregon, California, Massachusetts, Maryland, Germany, India, the UK, and Japan. For more information, please visit www.schrodinger.com.

DOWNLOAD PRESS RELEASE

Reveals Lead Programs in Cancer, Inflammation and Metabolic Disease

Highlights Unique Partnership with Schrödinger, The Leader in Computational Drug Discovery

CAMBRIDGE, Mass. – March 10, 2011 – Nimbus Discovery LLC, a biopharmaceutical company using state-of the-art computational technology to discover novel medicines against exciting but difficult-to-drug disease targets, today announced an extension of its seed round with an investment by Bill Gates and Dr. Richard Friesner, the co-founder of Schrödinger and Professor of Chemistry at Columbia University. Atlas Venture, the founding investor, also participated.

“I am excited to welcome Bill Gates and Richard Friesner as investors in Nimbus”, said Dr. Bruce Booth, Chairman and co-founder of Nimbus. “Their investment recognizes the unique opportunity Nimbus has to leverage Schrödinger’s 20-year technology investment with a virtually-integrated, globally distributed R&D approach.” The Nimbus financing follows a $10MM investment by Bill Gates in Schrödinger to accelerate R&D efforts.

The funds will be used to advance Nimbus’ lead programs in diffuse large B-cell lymphoma, an aggressive blood cancer, inflammatory disorders, and metabolic disease. Nimbus is targeting proteins that are pivotal for disease progression including IRAK4, a signaling kinase that becomes inappropriately activated in lymphoma and inflammation, and ACC, a metabolic enzyme that controls the synthesis and burning of fat. While traditional chemistry approaches have failed to develop medicines for these targets, the Nimbus team has generated selective, potent, and differentiated compounds within its first year. Over the next 12-18 months, Nimbus will refine clinical candidates for these targets and will expand its pipeline to include a new series of important targets.

The Nimbus pipeline is the product of a successful strategic partnership with Schrödinger, the leader in chemical simulation and in silico drug discovery, that grants Nimbus privileged access to leading-edge technology, including next-generation WaterMap™ and related technologies, and exclusive rights to key targets. Under the terms of the agreement established in 2010, Nimbus receives exclusive use of customized software packages developed by Schrödinger for these targets, access to a dedicated team of Schrödinger computational chemists and unlimited use of cloud computing resources. Schrödinger has a material equity stake in Nimbus and will receive a series of success-driven milestone payments.

Nimbus has assembled a team with deep drug-discovery experience including Rosana Kapeller M.D., Ph.D., co-founder of Aileron Therapeutics (Chief Scientific Officer); Jonathan Montagu, formerly Concert Pharmaceuticals Business Development (Vice President, Business Operations); Bruce Booth, Ph.D., Partner at Atlas Venture (Director); Vicki Sato, Ph.D., former President of Vertex Pharmaceuticals (Director); and Ramy Farid, Ph.D., co-founder of Nimbus Discovery and President of Schrödinger (Director).

About Nimbus Discovery, LLC

Nimbus Discovery is applying advances in computer-based drug discovery to develop new medicines against important drug targets and thereby unlock fundamental biological pathways. Nimbus has established a first-of-its-kind partnership with Schrödinger, the leader in computational drug discovery, to gain privileged access to cutting-edge technology and exclusive rights to key targets. Nimbus has already delivered selective, potent, and differentiated compounds within the first year for two disease targets that are pivotal in the progression of an aggressive form of Non-Hodgkin’s lymphoma and obesity, respectively. Nimbus has built a virtually integrated, globally distributed R&D organization that leverages an experienced internal drug discovery team across an external network of R&D partners. The resulting organization is scalable, capital efficient and has attracted world-class talent. Nimbus seeks to partner its programs with larger pharmaceutical companies early in the development process allowing Nimbus to focus on its competitive advantage in novel drug discovery. Nimbus programs are held in target-specific subsidiaries under an LLC umbrella. Nimbus Discovery was founded in 2009 by Atlas Venture and Schrödinger, Inc. In 2010, Nimbus received three Qualifying Therapeutic Discovery Project Tax Credit (QTDP) grants for its programs. For more information please visit www.nimbustx.com.

About Atlas Venture

Atlas Venture is a leading early-stage international venture capital firm that invests in technology and life sciences businesses. Since inception in 1980, its partners have helped build over 350 companies in more than 16 different countries. Atlas Venture is currently investing from its eighth fund which closed in late 2008. For more information, visit www.atlasventure.com.

About Schrödinger

Schrödinger is a scientific leader in developing state-of-the-art chemical simulation software for use in pharmaceutical and biotechnology research. The Company provides products ranging from general molecular modeling programs to a full-featured suite of drug design software using both ligand- and structure-based methods. The predictive power of Schrödinger’s software allows scientists to accelerate their research and development activities, reduce research costs, and make novel discoveries that might not be possible otherwise. Most recently, Schrödinger acquired the Seurat™ platform to add enterprise-wide data sharing and visualization to its complete offerings. Schrödinger operates from locations in New York, Oregon, California, Massachusetts, Maryland, Germany, India, and the UK. For more information, please visit www.schrodinger.com.

DOWNLOAD PRESS RELEASE